Literature DB >> 25351746

Immunomodulatory antibody therapy of cancer: the closer, the better.

Roxana S Dronca1, Haidong Dong2.   

Abstract

Immune checkpoint blockade therapies have demonstrated promising therapeutic effects; however, clinical outcomes are variable, with only a subgroup of cancer patients achieving durable complete responses. New therapeutic strategies, including local administration of immunomodulatory antibodies, have been considered as better routes for improving the overall efficacy of antibody-based therapy. ©2014 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25351746      PMCID： PMC4348171          DOI： 10.1158/1078-0432.CCR-14-2111

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  12 in total

1.  The Treatment of Inoperable Sarcoma by Bacterial Toxins (the Mixed Toxins of the Streptococcus erysipelas and the Bacillus prodigiosus).

Authors:  W B Coley
Journal:  Proc R Soc Med       Date:  1910

2.  The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.

Authors:  Sara M Mangsbo; Sissela Broos; Erika Fletcher; Niina Veitonmäki; Christina Furebring; Eva Dahlén; Per Norlén; Malin Lindstedt; Thomas H Tötterman; Peter Ellmark
Journal:  Clin Cancer Res       Date:  2014-10-14       Impact factor: 12.531

3.  Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells.

Authors:  Purevdorj B Olkhanud; Bazarragchaa Damdinsuren; Monica Bodogai; Ronald E Gress; Ranjan Sen; Katarzyna Wejksza; Enkhzol Malchinkhuu; Robert P Wersto; Arya Biragyn
Journal:  Cancer Res       Date:  2011-03-28       Impact factor: 12.701

4.  Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells.

Authors:  Sangeeta Shah; Anagha A Divekar; Shannon P Hilchey; Hyun-Mi Cho; Corliss L Newman; Seung-Uon Shin; Hovav Nechustan; Pia M Challita-Eid; Benjamin M Segal; Kyung Hee Yi; Joseph D Rosenblatt
Journal:  Int J Cancer       Date:  2005-11-20       Impact factor: 7.396

5.  Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

Authors:  Christian A Bauer; Edward Y Kim; Francesco Marangoni; Esteban Carrizosa; Natalie M Claudio; Thorsten R Mempel
Journal:  J Clin Invest       Date:  2014-05-08       Impact factor: 14.808

6.  Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Authors:  Min Dai; Huafeng Wei; Yuen Yee Yip; Qinghua Feng; Kecheng He; Viorica Popov; Ingegerd Hellstrom; Karl Erik Hellstrom
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

Review 7.  Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies.

Authors:  Ignacio Melero; Oihana Murillo; Juan Dubrot; Sandra Hervás-Stubbs; José L Perez-Gracia
Journal:  Trends Pharmacol Sci       Date:  2008-07-01       Impact factor: 14.819

8.  CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients.

Authors:  Paul A Blair; Lina Yassin Noreña; Fabian Flores-Borja; David J Rawlings; David A Isenberg; Michael R Ehrenstein; Claudia Mauri
Journal:  Immunity       Date:  2010-01-14       Impact factor: 31.745

9.  Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.

Authors:  Elizabeth D Thompson; Hilda L Enriquez; Yang-Xin Fu; Victor H Engelhard
Journal:  J Exp Med       Date:  2010-07-26       Impact factor: 14.307

10.  Endogenous tumor-reactive CD8+ T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth.

Authors:  Xin Liu; Rachel M Gibbons; Susan M Harrington; Christopher J Krco; Svetomir N Markovic; Eugene D Kwon; Haidong Dong
Journal:  Oncoimmunology       Date:  2013-06-06       Impact factor: 8.110
View more
  6 in total

1.  A T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy.

Authors:  Haidong Dong; Yiyi Yan; Roxana S Dronca; Svetomir N Markovic
Journal:  SOJ Immunol       Date:  2017-02-25

Review 2.  Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.

Authors:  Mariona Cabo; Rienk Offringa; Laurence Zitvogel; Guido Kroemer; Aura Muntasell; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-08-30       Impact factor: 8.110

Review 3.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

Review 4.  State of play and clinical prospects of antibody gene transfer.

Authors:  Kevin Hollevoet; Paul J Declerck
Journal:  J Transl Med       Date:  2017-06-07       Impact factor: 5.531

Review 5.  The Promise of Preventive Cancer Vaccines.

Authors:  Pier-Luigi Lollini; Federica Cavallo; Patrizia Nanni; Elena Quaglino
Journal:  Vaccines (Basel)       Date:  2015-06-17

6.  Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).

Authors:  A Marabelle; R Andtbacka; K Harrington; I Melero; R Leidner; T de Baere; C Robert; P A Ascierto; J-F Baurain; M Imperiale; S Rahimian; D Tersago; E Klumper; M Hendriks; R Kumar; M Stern; K Öhrling; C Massacesi; I Tchakov; A Tse; J-Y Douillard; J Tabernero; J Haanen; J Brody
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.